Article ID Journal Published Year Pages File Type
3990245 Journal of Thoracic Oncology 2013 8 Pages PDF
Abstract
The recommended phase II dose of capecitabine is 3500 mg when given concurrently with 50.4 Gy of thoracic radiotherapy in 28 fractions and weekly docetaxel. This trimodality therapy for operable locally advanced esophageal carcinoma was very well tolerated and remarkably active. This regimen holds promise for the treatment of esophageal carcinoma and warrants further investigation.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , , , ,